|
|
|
|
LEADER |
00000cam a2200000Ma 4500 |
001 |
SCIDIR_ocn233792237 |
003 |
OCoLC |
005 |
20231117015116.0 |
006 |
m o d |
007 |
cr zn||||||||| |
008 |
070921s2008 enk eo 000 0 eng d |
040 |
|
|
|a CDX
|b eng
|e pn
|c CDX
|d OCLCQ
|d IDEBK
|d OCLCQ
|d OPELS
|d OCLCQ
|d OCLCF
|d OCLCQ
|d EBLCP
|d OCLCQ
|d NLE
|d UKMGB
|d LEAUB
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
066 |
|
|
|c (S
|
015 |
|
|
|a GBB6H5420
|2 bnb
|
016 |
7 |
|
|a 017585202
|2 Uk
|
019 |
|
|
|a 935267626
|
020 |
|
|
|a 0080556515
|q (electronic bk.)
|
020 |
|
|
|a 9780080556512
|q (electronic bk.)
|
020 |
|
|
|a 9780123742247
|q (electronic bk.)
|
020 |
|
|
|a 0123742242
|q (electronic bk.)
|
035 |
|
|
|a (OCoLC)233792237
|z (OCoLC)935267626
|
050 |
|
4 |
|a RC267
|b .A38 2008eb
|
082 |
0 |
4 |
|a 616.9/94/0072 22 22
|2 22
|
245 |
0 |
0 |
|a Advances in cancer research.
|n Vol. 99.
|
260 |
|
|
|a London :
|b Elsevier :
|b Architectural Press,
|c 2008.
|
300 |
|
|
|a 1 online resource (432 pages).
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Advances in Cancer Research ;
|v v. 99
|
520 |
|
|
|a The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics including RUNX Genes in Development and Cancer; The RNA Continent; The c-myc Promoter; Designer Self-Assembling Peptide Nanofiber Scaffolds for Study of 3-D Cell Biology and Beyond; and Dendritic Cells in Cancer. Immunotherapy.
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Cover ; Advances in Cancer Research ; Copyright ; Contents ; Contributors ; FOUNDATIONS IN CANCER RESEARCH: The Turns of Life and Science ; I. To Write or Not to Write? ; II. Boys and Resurrection of Czechoslovakia ; III. University ; IV. Virogenic Cells and Provirus Integration.
|
505 |
8 |
|
|a V. Virus Rescue VI. Prague Spring 1968 ; VII. Dark Years ; VIII. Partial Thawing and Molecular Biology ; IX. Silencing the Provirus and the Red Power ; X. Epilogue ; Acknowledgments ; References.
|
505 |
8 |
|
|a II. EC Cells (Teratocarcinoma Stem Cells): The Biological Model That Led to the Identification of PEBP2III. Infection of EC Cells with Retroviruses; IV. Infection of EC Cells with Py ; V. Isolation and Analysis of PyEC Mutants ; VI. Isolation of PyTR Mutants ; VII. The Molecular Implications of PyFL and PyNB Mutants ; VIII. Dissection of the Py Enhancer ; IX. Developmental Regulation of Py Enhancer Subfragments in F9 and DF9 Cells ; X. Responsiveness of Py Enhancer a Element to Activated Ras and TPA ; XI. Identification of PEA2/PEBP2 ; XII. Why We Decided to Study PEBP2/RUNX Further?
|
650 |
|
0 |
|a Cancer
|x Research.
|
650 |
|
6 |
|a Cancer
|x Recherche.
|0 (CaQQLa)201-0004697
|
650 |
|
7 |
|a Cancer
|x Research
|2 fast
|0 (OCoLC)fst00845497
|
776 |
0 |
8 |
|i Print version:
|a Vande Woude, George F.
|t Advances in Cancer Research.
|d Burlington : Elsevier Science, �2014
|z 9780123742247
|
830 |
|
0 |
|a Advances in Cancer Research.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780123742247
|z Texto completo
|
880 |
8 |
|
|6 505-00/(S
|a XIII. Purification of PEBP2 Revealed That It Is a Heterodimer Composed of Two Subunits XIV. cDNA Cloning of PEBP2αA; XV. cDNA Cloning of PEBP2�
|